Development of Neuroprotective Agents for the Treatment of Alzheimer's Disease using Conjugates of Serotonin with Sesquiterpene Lactones
Authors:
- Margarita NeganovaMargarita Neganova
- Junqi LiuJLJunqi Liu
- Yulia AleksandrovaYAYulia Aleksandrova
- Natalia VasilievaNVNatalia Vasilieva
- Alexey SemakovASAlexey Semakov
- Ekaterina YandulovaEYEkaterina Yandulova
- Olga SukochevaOlga Sukocheva
- Konstantin BalakinKBKonstantin Balakin
- Sergey KlochkovSKSergey Klochkov
- Ruitai FanRFRuitai Fan
- 1 February 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 31 (5) , 529-551
Abstract
Background: Sesquiterpene lactones are secondary plant metabolites with a wide variety of biological activities. The process of lactone conjugation to other pharmacophores can increase the efficacy and specificity of the conjugated agent effect on molecular targets in various diseases, including brain pathologies. Derivatives of biogenic indoles, including neurotransmitter serotonin, are of considerable interest as potential pharmacophores. Most of these compounds have neurotropic activity and, therefore, can be used in the synthesis of new drugs with neuroprotective properties. Aim: The aim of this experimental synthesis was to generate potential treatment agents for Alzheimer's disease using serotonin conjugated with natural sesquiterpene lactones. Methods: Three novel compounds were obtained via the Michael reaction and used for biological testing. The obtained conjugates demonstrated complex neuroprotective activities. Serotonin conjugated to isoalantolactone exhibited strong antioxidant and mitoprotective activities. Results: The agent was also found to inhibit β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), prevent the aggregation of β-amyloid peptide 1-42, and protect SH-SY5Y neuroblastoma cells from neurotoxins such as glutamate and H2O2. In a transgenic animal model of Alzheimer's disease (5xFAD line), the conjugated agent restored declined cognitive functions and improved learning and memory. Conclusion: In conclusion, the obtained results indicate that serotonin conjugates to sesquiterpene lactones are promising agents for the treatment of symptoms associated with Alzheimer's disease.Keywords
Funding Information
- State Assignment of IPAC RAS (0090-2019-0006)
- Applied Genetics Resource Facility of MIPT (075-15-2021-684)
This publication has 64 references indexed in Scilit:
- Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson diseaseFree Radical Biology and Medicine, 2013
- A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinHuman Molecular Genetics, 2013
- Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease?Molecular Neurobiology, 2010
- Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado‐Joseph diseaseJournal of Neuroscience Research, 2009
- Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque FormationThe Journal of Neuroscience, 2006
- A “mitochondrial cascade hypothesis” for sporadic Alzheimer's diseaseMedical Hypotheses, 2004
- Apoptotic vs. Nonapoptotic Cytotoxicity Induced by Hydrogen PeroxideFree Radical Biology and Medicine, 1997
- Oxidative Stress in Neurodegenerative DiseasesAnnual Review of Pharmacology and Toxicology, 1996
- A Practicable Synthesis of 3-(2-Aminoethyl)-1H-indol-5-yl Hydrogen Sulfate (SerotoninO-Sulfate)Synthesis, 1983
- Safranine as a probe of the mitochondrial membrane potentialFEBS Letters, 1976